Cocrystal Pharma Announces Abstract Accepted for Oral Presentation at the ISIRV: Options X for the Control of Influenza Conference - Nasdaq

Cocrystal Pharma Announces Abstract Accepted for Oral Presentation at the ISIRV: Options X for the Control of Influenza Conference  Nasdaq

BOTHELL, WA, Aug. 21, 2019-- Cocrystal Pharma, Inc.,, a clinical stage biotechnology company discovering and developing novel antiviral.



Comments

Popular posts from this blog